
BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPRlVSZ2lyYmxVTHRibEdwQmV1R0ZLbkRlMGg0TldhbWxYT0FvVnlBcDNmWmNhZkswWjVPV2Q5c0ZmSlozaERIQm12Q0I4Q1lqNXBnNE1rNjQ2b3ZZbjJQSGF6dGlYU1pXb2lmS3FCOFRjMnQyVm13X1gxSVdmeE41ZHR5MTVkbWxFbWJjVjdaSjhXNXB5V0ktTUZSa0tuVDhWWmkzS3BqNkYxVHJzTi1OeVF3VXhGemlGTGJOOUZMUS01UXpDdTBObkFCZw?oc=5" target="_blank">BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>

